01652 FUSEN PHARM
- 1.150
- 0.0000.00%
FUSEN PHARM News
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Insider Buying: Fusen Pharmaceutical Executive Chairman Bought CN¥908k Of Shares
Investors who take an interest in Fusen Pharmaceutical Company Limited (HKG:1652) should definitely note that the Executive Chairman, Changcheng Cao, recently paid HK$0.87 per share to buy HK$908k wor
福森藥業：年報2023
Fuson Pharmaceuticals (01652.HK) was granted by Full Bliss Holdings Limited to increase its common share holdings by 650,000 shares worth approximately HK$575,300
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Full Bliss Holdings Limited increased its share holdings of $Fussen Pharmaceuticals (01652.HK) by $650,000 at an average price of HK$0.885 per share on April 19, worth approximately HK$575,300. After the increase in holdings, Full Bliss Holdings Limited's latest shareholding was 205 million shares, and the good position ratio increased from 27.30% to 27.39%. This transaction involves other related parties: Cao Changcheng and Quan Xiufeng. pictures
Fuson Pharmaceuticals (01652.HK) was granted by Full Bliss Holdings Limited to increase its common share holdings by 1.041 million shares, worth approximately HK$907,500
On April 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 25, Full Bliss Holdings Limited increased its share holdings of $Fussen Pharmaceuticals (01652.HK) by $1.041 million at an average price of HK$0.8718 per share on April 22, worth about HK$907,500. After the increase in holdings, Full Bliss Holdings Limited's latest shareholding was 206 million shares, and the good position ratio rose from 27.39% to 27.53%. This transaction involves other related parties: Cao Changcheng and Quan Xiufeng
Fuson Pharmaceuticals (01652.HK) was granted by One Victory Investments Limited to increase its common stock holdings by 240,000 shares worth approximately HK$212,000
On April 24, it was reported that, according to documents disclosed by the Hong Kong Stock Exchange on April 24, One Victory Investments Limited increased its share holdings of $Fussen Pharmaceuticals (01652.HK) by $240,000 at an average price of HK$0.8833 per share on April 18, worth approximately HK$212,000. After the increase in holdings, One Victory Investments Limited's latest shareholding was 155 million shares, and the good position ratio increased from 20.59% to 20.62%. This transaction involves other related parties: Quan Xiufeng
Forson Pharmaceutical (01652.HK): Application for marketing license for “Compound Potassium Hydrogen Phosphate Injection” was accepted
Gelonghui, April 23 | Forson Pharmaceutical (01652.HK) announced that the compound potassium hydrogen phosphate injection developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: as a phosphorus supplement in complete parenteral nutritional therapy; it can also be used for hypophosphatemia caused by certain diseases. Phosphorus is involved in sugar phosphorylation in sugar metabolism, making up phospholipids in membrane components, and is an important component of RNA, DNA, and many coenzymes in cells. Phosphorus is also involved in energy storage, conversion, and body fluid buffering functions
Fuson Pharmaceuticals (01652.HK) received 265,000 additional shares of common stock worth approximately HK$223,700 from One Victory Investments Limited
On April 23, it was reported that, according to documents disclosed by the Hong Kong Stock Exchange on April 23, One Victory Investments Limited increased its share holdings of $265,000 of $Fussen Pharmaceuticals (01652.HK) with an average price of HK$0.8442 per share on April 17, worth approximately HK$223,700. After the increase in holdings, One Victory Investments Limited's latest shareholding was 154 million shares, and the good position ratio increased from 20.55% to 20.59%. This transaction involves other related parties:
Repurchase Collection on April 17 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$226 million
According to HKEx's April 18 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.6 million common shares on April 16, involving an amount of HK$226 million. The repurchase price per share ranged from HK$63.05 to HK$62.25. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 17, involving an amount of HK$57.427,600. The repurchase price per share ranged from HK$96.65 to 94.9
Forson Pharmaceutical (01652) spent about HK$546,900 to buy back 648,000 shares on April 17
Forson Pharmaceutical (01652) announced that on April 17, 2024, it cost about HK$546,900 to buy back 64.8...
Repurchase Collection on April 16 | HSBC Holdings, Changshi Group, etc. bought back one after another, of which HSBC Holdings spent HK$206 million
According to documents disclosed by the Hong Kong Stock Exchange on April 17, $HSBC Holdings (00005.HK) $, $Changshi Group (01113.HK) $, etc. repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.2412 million common shares on April 15, involving an amount of HK$206 million. The repurchase price per share ranged from HK$63.85 to HK$63.1. ② $Changshi Group (01113.HK) $ repurchased 2,434,500 common shares on April 16, involving an amount of HK$76.3271 million, with a repurchase price of HK$31.4 per share
Forson Pharmaceuticals (01652.HK) spent HK$581,500 to buy back 676,000 shares on April 16
On April 16, Gelonghui | Forson Pharmaceutical (01652.HK) announced that it spent HK$581,500 to buy back 676,000 shares on April 16.
Fussen Pharmaceutical (01652.HK) plans to establish a limited partnership to explore diversified business development
Gelonghui, April 16, 丨 Fussen Pharmaceutical (01652.HK) announced that on April 16, 2024, Henan Fusen, an indirect wholly-owned subsidiary of the company (as limited partner A), entered into a limited partnership agreement with the general partner and limited partner B to establish a limited partnership. Henan Fusen's total capital commitment is RMB 85 million, which will be disbursed using the Group's internal resources. The limited partnership will engage in investment business and participate in investing in different potential pharmaceutical-related enterprises or projects. Qingdao Qiji Electronic Technology Co., Ltd. is a limited company established in China. Limited partner B is mainly engaged in corporate investment and equity
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Analysis
Price Target
No Data
